Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tavipec is a herbal medicinal product developed by Pharmazeutische Fabrik Montavit for the treatment of respiratory tract disorders. Its active ingredient is 150 mg of spike lavender oil (*Lavandula latifolia* essential oil), obtained via steam distillation of the flowering tops. Formulated as enteric-coated soft capsules for oral administration, Tavipec acts as a secretolytic and expectorant, facilitating the liquefaction of viscous mucus and enhancing mucociliary clearance. It also exhibits bronchospasmolytic, antiseptic, and anti-inflammatory properties. The drug is primarily indicated for the treatment of acute and chronic rhinosinusitis, acute and chronic bronchitis, and coughs associated with the common cold. The enteric coating ensures that the essential oil is released in the small intestine, avoiding gastric irritation and ensuring systemic absorption to reach the respiratory tract.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tavipec.